Coherus Oncology reports Q2 2026 growth; pipeline milestones set up 2H 2026
Aug 5, 2026, 4:32 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Strong LOQTORZI growth (Q2 revenue up 37% YoY) provides near-term revenue visibility, while multiple 2H 2026 data readouts for Tagmokitug and Casdozokitug create upside optionality. However, ongoing cash burn (GAAP and non-GAAP losses) and a reduced cash balance ($105.3M) are overhangs that cap upside if data disappoints or funding becomes tight. Historically, positive phase data and continued LOQTORZI adoption can drive multiple expansion, but liquidity and execution risks remain.
AI summary
What happened, with direct paths to the underlying reporting
Coherus posted Q2 2026 continuing-net revenue of $14.3M, up from $10.3M a year ago, led by LOQTORZI. LOQTORZI Q2 revenue was $13.6M, up 37% YoY and higher than Q1. The company cites advancing tagmokitug and casdozokitug with 2H 2026 data reads, plus October data disclosure.
Q2 2026 continuing net revenue: $14.3M; up from $10.3M in 2025.
LOQTORZI Q2 revenue: $13.6M; YoY +37% and higher vs Q1.
2H 2026 data readouts expected for tagmokitug and casdozokitug; October data disclosure planned.
Casdozokitug enrollment complete in 1L uHCC; Tagmokitug studies in HNSCC/CRC advancing.
Conference call scheduled for Aug 5, 2026 at 5:00 p.m. ET.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Coherus divests Udenyca for up to $558.4 million. Proceeds will repay $230 million in convertible notes. Coherus aims to focus on its immuno-oncology portfolio. Phase 2 trials for…
